Blocking Assay:Article Title: A promising magnesium-related alloy with metabolic reprogramming and antitumor effects in hepatocellular and pancreatic cancer
Article Snippet: Equal amounts of protein were separated by SDS-PAGE and transferred onto PVDF membranes (Millipore, LG18-1501M − 1H). .. After blocking with 5 % nonfat milk for 1 h at room temperature, membranes were incubated overnight at 4 °C with primary antibodies, including AMPK (1:1000, CST, 2532), p-AMPK (1:1000, CST, 2535), CPT1B (1:1000, Proteintech, 22170-1-AP), CDK4 (1:1000, Proteintech, 11026-1-AP), PCNA (1:1000, Proteintech, 10205-2-AP), p21 (1:1000, Proteintech, 10355-1-AP), GAPDH (1:1000, Proteintech, 60004-1-Ig) followed by HRP-conjugated secondary antibody (1:5000, Proteintech, RGAR001) for 1 h at room temperature. ..
Incubation:Article Title: A promising magnesium-related alloy with metabolic reprogramming and antitumor effects in hepatocellular and pancreatic cancer
Article Snippet: Equal amounts of protein were separated by SDS-PAGE and transferred onto PVDF membranes (Millipore, LG18-1501M − 1H). .. After blocking with 5 % nonfat milk for 1 h at room temperature, membranes were incubated overnight at 4 °C with primary antibodies, including AMPK (1:1000, CST, 2532), p-AMPK (1:1000, CST, 2535), CPT1B (1:1000, Proteintech, 22170-1-AP), CDK4 (1:1000, Proteintech, 11026-1-AP), PCNA (1:1000, Proteintech, 10205-2-AP), p21 (1:1000, Proteintech, 10355-1-AP), GAPDH (1:1000, Proteintech, 60004-1-Ig) followed by HRP-conjugated secondary antibody (1:5000, Proteintech, RGAR001) for 1 h at room temperature. ..
Article Title: Glioma Cell-Derived Apoptotic Extracellular Vesicles Promote Tumorigenesis and Temozolomide Resistance by Delivering LncRNA-XIST.
Article Snippet: Gliomas are characterized by high incidence, high recurrence rate, high malignancy, high aggressiveness, high therapeutic difficulty, poor clinical prognosis, and high mortality.. Therefore, overcoming temozolomide (TMZ) resistance in glioma has become a research hotspot.. This study will investigate the effects of glioma cell‐derived apoptotic extracellular vesicles (apoEVs) on tumorigenesis and TMZ resistance in glioma. apoEVs derived from TMZ‐induced apoptotic glioma cells were isolated, extracted, and characterized.
Knock-Out:Article Title: CGP60474, a novel MITD1-targeted inhibitor for bladder cancer progression via CDK4/cyclin D1 pathway modulation
Article Snippet: .. Antibodies against MITD1 (17264-1-AP, Proteintech), Tubulin (66240-1-Ig, Proteintech), β-Actin (66009-1-Ig, Proteintech), CDK4 (11026-1-AP, 66950-1-Ig, Proteintech), cyclin D1 (26939-1-AP, 60186-1-Ig, Proteintech), DYKDDDDK tag Monoclonal Fig. 7 | Genetic knockout ofMITD1 via CRISPR-Cas9 impairs proliferation and induces cell cycle arrest in UMUC-3 cells. ..
CRISPR:Article Title: CGP60474, a novel MITD1-targeted inhibitor for bladder cancer progression via CDK4/cyclin D1 pathway modulation
Article Snippet: .. Antibodies against MITD1 (17264-1-AP, Proteintech), Tubulin (66240-1-Ig, Proteintech), β-Actin (66009-1-Ig, Proteintech), CDK4 (11026-1-AP, 66950-1-Ig, Proteintech), cyclin D1 (26939-1-AP, 60186-1-Ig, Proteintech), DYKDDDDK tag Monoclonal Fig. 7 | Genetic knockout ofMITD1 via CRISPR-Cas9 impairs proliferation and induces cell cycle arrest in UMUC-3 cells. ..
Western Blot:Article Title: DMAP1 Deficiency Suppresses Lung Cancer Progression by Destabilizing Replication Fork and Activating IFN Signaling-Mediated Anti-tumor Immunity.
Article Snippet: .. Western blot antibodies used in this study: DMAP1 (10411-1-AP), CDK4 (11026-1-AP), Cyclin E2 (85803-3-RR), PARP1 (13371-1-AP), GAPDH (60004-1-Ig), Vinculin (66305-1-Ig), β-Tubulin (66240-1- Ig), and β-Actin (66009-1-Ig) antibodies were from Proteintech; Phospho-Chk2 (Thr68) (HY-P80799), RPA32/RPA2 (HY-P80975), Chk1 (HY-P80082), and Chk2 (HY-P80083) antibodies were from MCE; Rad51 (F1110), CDK2 (F0022), CDK6 (F0372), Cyclin A2 (F1033), Cyclin B1 (F2522), Cyclin D1 (F2524), Phospho-CDK1 (Thr161) + CDK2/3 (Thr160) (F3185), Phospho-CDK1/2/3 (Thr14) (F2120), RPA-pS33 (F2375), MCM2 (F0581), and PCNA (F0018) antibodies were from Selleck; Phospho-Chk1 (Ser345) (2348), Phospho-ATM (Ser1981) (5883), Phospho-TBK1 (Ser172) (5483), TBK1 (38066), Phospho-STING (Ser365) (72971), STING (13647), Phospho-Stat1 (Tyr701) (9167), Stat1 (14994), Phospho-IRF-7 (Ser437/438) (24129), IRF-7 (72073), Phospho-IRF-3 (Ser396) (4947), IRF-3 (4302), HA-Tag (3724), MAR/PAR (89190), and Phospho-ATR (Ser428) (2853) antibodies were from CST; CDK1 (A11420) antibody and Rabbit control IgG (AC005) were from Abclonal; Phospho-CDK6 (Tyr24) (AF2440) and Phospho-CDK4 (Thr172) (AF8007) antibodies were from Affinity Biosciences; Goat Anti-Rabbit IgG-HRP (CW0103) and Goat Anti-Mouse IgG-HRP (CW0102) antibodies were from CWBIO. .. Reagents and chemicals used in this study inclu CldU (MCE, HY-112669), IdU (MCE, HY-B0307), Vadimezan (Selleck, S1537), Nelfinavir (TargetMol, T7779), AG99 (TargetMol, T5155), Nicardipine (TargetMol, T1215), Pantoprazole (TargetMol, T6928), Lidocaine (TargetMol, T1144), Fulvestrant (TargetMol, T2146), Dydrogesterone (TargetMol, T3036), Carbenoxolone (TargetMol, T0992), Metoprolol (TargetMol, T0487), Moxifloxacin (TargetMol, T0331L), Cilomilast (Selleck, S1455), Avasimibe (Selleck, S2187), and Dacinostat (TargetMol, T2454).
Recombinase Polymerase Amplification:Article Title: DMAP1 Deficiency Suppresses Lung Cancer Progression by Destabilizing Replication Fork and Activating IFN Signaling-Mediated Anti-tumor Immunity.
Article Snippet: .. Western blot antibodies used in this study: DMAP1 (10411-1-AP), CDK4 (11026-1-AP), Cyclin E2 (85803-3-RR), PARP1 (13371-1-AP), GAPDH (60004-1-Ig), Vinculin (66305-1-Ig), β-Tubulin (66240-1- Ig), and β-Actin (66009-1-Ig) antibodies were from Proteintech; Phospho-Chk2 (Thr68) (HY-P80799), RPA32/RPA2 (HY-P80975), Chk1 (HY-P80082), and Chk2 (HY-P80083) antibodies were from MCE; Rad51 (F1110), CDK2 (F0022), CDK6 (F0372), Cyclin A2 (F1033), Cyclin B1 (F2522), Cyclin D1 (F2524), Phospho-CDK1 (Thr161) + CDK2/3 (Thr160) (F3185), Phospho-CDK1/2/3 (Thr14) (F2120), RPA-pS33 (F2375), MCM2 (F0581), and PCNA (F0018) antibodies were from Selleck; Phospho-Chk1 (Ser345) (2348), Phospho-ATM (Ser1981) (5883), Phospho-TBK1 (Ser172) (5483), TBK1 (38066), Phospho-STING (Ser365) (72971), STING (13647), Phospho-Stat1 (Tyr701) (9167), Stat1 (14994), Phospho-IRF-7 (Ser437/438) (24129), IRF-7 (72073), Phospho-IRF-3 (Ser396) (4947), IRF-3 (4302), HA-Tag (3724), MAR/PAR (89190), and Phospho-ATR (Ser428) (2853) antibodies were from CST; CDK1 (A11420) antibody and Rabbit control IgG (AC005) were from Abclonal; Phospho-CDK6 (Tyr24) (AF2440) and Phospho-CDK4 (Thr172) (AF8007) antibodies were from Affinity Biosciences; Goat Anti-Rabbit IgG-HRP (CW0103) and Goat Anti-Mouse IgG-HRP (CW0102) antibodies were from CWBIO. .. Reagents and chemicals used in this study inclu CldU (MCE, HY-112669), IdU (MCE, HY-B0307), Vadimezan (Selleck, S1537), Nelfinavir (TargetMol, T7779), AG99 (TargetMol, T5155), Nicardipine (TargetMol, T1215), Pantoprazole (TargetMol, T6928), Lidocaine (TargetMol, T1144), Fulvestrant (TargetMol, T2146), Dydrogesterone (TargetMol, T3036), Carbenoxolone (TargetMol, T0992), Metoprolol (TargetMol, T0487), Moxifloxacin (TargetMol, T0331L), Cilomilast (Selleck, S1455), Avasimibe (Selleck, S2187), and Dacinostat (TargetMol, T2454).
Control:Article Title: DMAP1 Deficiency Suppresses Lung Cancer Progression by Destabilizing Replication Fork and Activating IFN Signaling-Mediated Anti-tumor Immunity.
Article Snippet: .. Western blot antibodies used in this study: DMAP1 (10411-1-AP), CDK4 (11026-1-AP), Cyclin E2 (85803-3-RR), PARP1 (13371-1-AP), GAPDH (60004-1-Ig), Vinculin (66305-1-Ig), β-Tubulin (66240-1- Ig), and β-Actin (66009-1-Ig) antibodies were from Proteintech; Phospho-Chk2 (Thr68) (HY-P80799), RPA32/RPA2 (HY-P80975), Chk1 (HY-P80082), and Chk2 (HY-P80083) antibodies were from MCE; Rad51 (F1110), CDK2 (F0022), CDK6 (F0372), Cyclin A2 (F1033), Cyclin B1 (F2522), Cyclin D1 (F2524), Phospho-CDK1 (Thr161) + CDK2/3 (Thr160) (F3185), Phospho-CDK1/2/3 (Thr14) (F2120), RPA-pS33 (F2375), MCM2 (F0581), and PCNA (F0018) antibodies were from Selleck; Phospho-Chk1 (Ser345) (2348), Phospho-ATM (Ser1981) (5883), Phospho-TBK1 (Ser172) (5483), TBK1 (38066), Phospho-STING (Ser365) (72971), STING (13647), Phospho-Stat1 (Tyr701) (9167), Stat1 (14994), Phospho-IRF-7 (Ser437/438) (24129), IRF-7 (72073), Phospho-IRF-3 (Ser396) (4947), IRF-3 (4302), HA-Tag (3724), MAR/PAR (89190), and Phospho-ATR (Ser428) (2853) antibodies were from CST; CDK1 (A11420) antibody and Rabbit control IgG (AC005) were from Abclonal; Phospho-CDK6 (Tyr24) (AF2440) and Phospho-CDK4 (Thr172) (AF8007) antibodies were from Affinity Biosciences; Goat Anti-Rabbit IgG-HRP (CW0103) and Goat Anti-Mouse IgG-HRP (CW0102) antibodies were from CWBIO. .. Reagents and chemicals used in this study inclu CldU (MCE, HY-112669), IdU (MCE, HY-B0307), Vadimezan (Selleck, S1537), Nelfinavir (TargetMol, T7779), AG99 (TargetMol, T5155), Nicardipine (TargetMol, T1215), Pantoprazole (TargetMol, T6928), Lidocaine (TargetMol, T1144), Fulvestrant (TargetMol, T2146), Dydrogesterone (TargetMol, T3036), Carbenoxolone (TargetMol, T0992), Metoprolol (TargetMol, T0487), Moxifloxacin (TargetMol, T0331L), Cilomilast (Selleck, S1455), Avasimibe (Selleck, S2187), and Dacinostat (TargetMol, T2454).
other:
|
Proteintech is a verified supplier 